BioDiem reports new chair, increased loss
26 August, 2005 by Ruth BeranAustralian corporate leader Hugh Morgan is the new chairman of Melbourne-based flu vaccine company BioDiem (ASX:BDM) which has reported an increased loss of AUD$4.2 million in 2004-05, up 32 per cent from the last financial year.
Why investors are the missing link to biotech's success
26 August, 2005 by Peter AndrewsScientists, industry and government are doing their bit to develop the Australian biotechnology industry, writes Peter Andrews -- so where are the investors?
CSL grants Merck licence for Iscomatrix
24 August, 2005 by Ruth BeranAustralia's biggest biotech, Melbourne's CSL (ASX:CSL) has signed a license and option agreement with Merck & Co, granting the New Jersey-based pharmaceutical company certain rights and options to use CSL's Iscomatrix adjuvant in its pipeline of investigational vaccine products.
Sales drive up CogState revenues
24 August, 2005 by Helen SchullerMelbourne-based neurodiagnostic specialist CogState (ASX:CGS) has reported revenues of AUD$1.5 million for the financial year ending June 30 2005, nearly three times more than the previous corresponding period, largely through sales to major pharmaceutical companies and research institutions.
Event to focus on funding
23 August, 2005 by Staff WritersA breakfast meeting in Sydney this Friday will explore ways in which technology-based companies can get their hands on Commonwealth and NSW government grants.
$1m up for grabs in Qld grants
22 August, 2005 by Staff WritersThe Queensland government is offering $950,000 to local entrepreneurs in its start-up scheme, double the amount offered in previous years.
Find the right investor, biotechs warned
18 August, 2005 by Helen SchullerBiotechnology companies should not take money from just anybody, a meeting in Sydney heard this morning.
In brief: Select Vaccines, Life Therapeutics, Chemeq
17 August, 2005 by Ruth BeranSelect Vaccines' (ASX:SLT) executive chairman Jeremy Cooper has retired as a director and will be replaced by Robin Beaumont as non-executive chairman. Dr Martin Soust has become the Select Vaccines' full-time managing director, relinquishing his role as part-time CEO at Premier Bionics (ASX:PBI) but remaining with the company as a non-executive director. Peter Marks has been appointed as a non-executive director for Select Vaccines.
Giaconda aims for Sept IPO
17 August, 2005 by Helen SchullerSydney-based gastrointestinal drug development company Giaconda, has opened its initial public offering and plans to list on the ASX in late September, with the aim of raising AUD$6 million.
IDT posts record revenue, profit and dividends
17 August, 2005 by Ruth BeranPharmaceutical manufacturing and drug development company Institute of Drug Technology Australia (ASX:IDT) has reported an operating profit after tax of AUD$4.5 million for the year ended June 30, representing an increase of 5 per cent over the previous year.
Resonance to provide FerriScan to US research institutes
17 August, 2005 by Helen SchullerResonance Health Analysis Services (RHAS), a subsidiary of Perth-based Resonance Health (ASX:RHT) and formerly known as Inner Vision Biometrics, has agreed to provide its FerriScan diagnostic test to the New England Research Institutes (NERI) for use in its clinical studies.
Boost for medical research in Queensland
17 August, 2005 by Helen SchullerMedical research in Queensland has won a jackpot, with unclaimed first division lotto prizes to be transformed into grants for research and equipment.
Why biotech companies don't work
17 August, 2005 by Iain ScottAustralian Biotechnology News editor-in-chief Iain Scott spoke with renowned industry analyst Cynthia Robbins-Roth about what it will take to keep biotech alive.
Merck exec calls for biotech critical mass
15 August, 2005 by Ruth BeranThe oft-repeated cliche that Australia 'punches above its weight' in biotechnology is little more than a security blanket, and needs to be replaced with some real muscle, Merck Sharp & Dohme's external licensing coordinator, Graham Macdonald, told a meeting on Friday.
EG Capital tips market upswing
12 August, 2005 by Helen SchullerIn the wake of its annual Australian Biotechnology Expo, held earlier this week in Sydney, EG Capital executive director Alison Coutts is optimistic that the Australian biotech sector is on the way back up.
